FOR IMMEDIATE RELEASE

October 18, 2004.

Increased Emphasis on Downstream Processing Key Trend in Biopharmaceuticals Market.

London, UK - October 18th, 2004 - The reduced efficacy of existing drugs and a lack of treatments for many new diseases are expected to drive expansion in the biopharmaceuticals market. To benefit from this opportunity, participants must focus on improving the competence of downstream processing, which has been a long-standing time-scale and technology bottleneck in an otherwise efficient manufacturing process.

Limited investment and lack of innovation in downstream processing accounts for 40 per cent of biopharmaceutical production expenses and result in costly delays.

New analysis from Frost & Sullivan (www.biotech.frost.com), World Strategic Analysis of Downstream Processing in Biopharmaceuticals
Production, reveals that the contract manufacturing revenue in this market totalled USD 3.8 billion in 2004 and is projected to reach USD 9.2 billion in 2010.

Historically, there has been a lack of interest in downstream processing in comparison to upstream technologies. However, these issues are now being addressed through the development of innovative technologies by new investors and the existing multinationals.

"Trends include a move toward high-throughput membrane chromatography systems and the provision of integrated technology solutions," says Frost & Sullivan Research Analyst Phil Webster. "Participants are investing in increased volumetric throughput of apparatus and automated systems to increase production efficiency."

The cost of installing or developing in-house downstream systems and staying abreast of technology developments is encouraging drug discovery firms to outsource different stages of manufacturing of their procedures. As a result, contract manufacturing organisations (CMOs) are gaining prominence.

CMOs, in turn, are developing their own infrastructure to offer improved facilities for gaining a foothold in an increasingly competitive market. Due to this, investment in R&D is also expected to increase.

Another market driver is the growing competition for benchmark apparatus and consumables in the biopharmaceuticals market. This is compelling participants to develop original technologies to out-perform existing systems. Participants are also forming tactical alliances with other technology providers to provide end users with enhanced integrated solutions.

The Strategic Analysis of Downstream Processing in Biopharmaceuticals Production is a part of the Biotechnology subscription. The study offers a comprehensive overview of downstream processing technology dynamics and the worldwide CMO market. It also provides in-depth information on industry trends, revenue forecasts, market drivers, and challenges that is anticipated to help participants in effectively identifying and capitalising on growth opportunities. Analyst interviews are available to the press.

If you are interested in an analysis overview providing summary, challenges and latest trends in Downstream Processing in Biopharmaceuticals Production - then send an email to Katja Feick -Corporate Communications at katja.feick@frost.com with the following information: Full name, Company Name, Title, Contact Tel Number, Email. Upon receipt of the above information, an overview will be emailed to you.

Background
Frost & Sullivan, an international growth consultancy, has been supporting clients' expansion for more than four decades. Our market
expertise covers a broad spectrum of industries, while our portfolio of advisory competencies includes custom strategic consulting, market
intelligence, and management training. Our mission is to forge partnerships with our clients' management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan's network of consultants, industry experts, corporate trainers, and support staff spans the globe with offices in every major country.

CONTACTS: